Do you have questions about using checkpoint inhibitors in the urology clinic? Listen as EIOCC faculty Rajesh Nair, FRCS (Urol), FEBU, MSc (Urol), describes the urgent need for urologists to better understand IO therapies and their appropriate use in patients with renal and bladder cancers.
What is the future of IO therapy in renal and bladder cancers? Listen as EIOCC faculty Maria Carmen Mir, MD, PhD, and Mario W. Kramer, MD, discuss the emerging role of immune checkpoint inhibitors in patient care.
The University of Manchester Innovation Centre (UMIC)